Applied Filters
Takeda, Arbor aim to stop Turkish copies of high blood pressure drug
Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.
Generic Emcure stole COVID-19 vaccine trade secrets, lawsuit claims
US pharma company HDT Bio has accused Emcure Pharmaceuticals of the “blatant theft” of its COVID-19 vaccine technology in a new lawsuit.
Otsuka says Samsca generic infringes
Otsuka Pharmaceuticals has filed a patent infringement suit against MSN Laboratories targeting the company’s planned generic Samsca heart medication.
AbbVie and Alvotech settle all US Humira litigation
AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).
Cipla files defensive patent suit over Ofev generic
Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.
A&O recruits five-strong Goodwin team, launches in Boston
Allen & Overy has hired five partners from Goodwin Procter to boost its US life sciences litigation practice.
Otsuka says Teva’s REXULTI generic infringes patents
Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Janssen seeks to halt generic schizophrenia drug
Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate).
Pfizer sues Teva over arthritis treatment
Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires.
Judge partially revives California pay-for-delay ban
A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.
